Post hoc analysis of AVERT and AVERT-2 (ACPA-positive early RA): DAS28-CRP remission at 6/12 months was 27%/39% with methotrexate (n=388) and 43%/53% with abatacept plus methotrexate (n=743); only baseline DAS28 and early response consistently predicted remission.
Secondary analysis
Bergstra et al. Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials